Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lutathera
Pharma
FDA approves first radioligand equivalent
Bexlutry got its approval through the FDA’s 505(b)(2) pathway, a hybrid new drug application process that allows for reliance on reference data.
Angus Liu
Sep 15, 2026 8:38am
Novartis details plan for 2nd new US radiopharma plant
Feb 25, 2026 9:55am
Novartis charts next US investment with new radiopharma plant
Jan 9, 2026 10:30am
CHMP signs off on GSK's comeback ADC cancer drug Blenrep
May 23, 2025 11:23am
Novartis filed patent lawsuits in defense of radiopharma meds
Nov 4, 2024 10:48am
Novartis brings isotope production in house amid global shortage
Sep 4, 2024 11:24am
